Aberrant N-cadherin expression in cancer - 18/09/19
pages | 7 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | N-cadherin is aberrantly expressed in many cancers. |
• | Soluble N-cadherin level is upregulated in the serum of cancer patients. |
• | N-cadherin expression promotes cancer metastasis, invasion, adhesion, apoptosis and angiogenesis. |
• | The expression of N-cadherin is regulated by many regulatory factors, such as β-catenin, TGF-β, NF-κB, Notch, miR-145, etc. |
Abstract |
Neural (N)-cadherin is a calcium-dependent single-chain transmembrane glycoprotein that mediates homotypic and heterotypic cell-cell adhesion. As an important member of the cadherin family, N-cadherin plays an important role in the developmental and functional regulation of the nervous system, brain, heart, skeletal muscles, blood vessels and hematopoietic microenvironment. However, aberrant expression of N-cadherin has been found in many cancers, such as lung cancer, breast cancer, prostate cancer and squamous cell carcinoma. It is increasingly recognized that aberrant expression of N-cadherin is closely related to aspects of malignant tumor progression in humans, such as transformation, adhesion, apoptosis, angiogenesis, invasion and metastasis, suggesting that N-cadherin can be a therapeutic target for tumor invasion and metastasis. This minireview summarizes the diverse roles of N-cadherin in cancer progression and the regulatory factors that affect the expression of N-cadherin in cancer, findings that increase our awareness of the importance of developing new therapeutic agents targeting N-cadherin.
Le texte complet de cet article est disponible en PDF.Keywords : N-cadherin, Cancer, Aberrant expression, Metastasis
Plan
Vol 118
Article 109320- octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?